Close menu




August 17th, 2021 | 11:12 CEST

Memiontec, Bayer, Aurubis - Do not miss this trend!

  • Investments
Photo credits: pixabay.com

According to estimates by some experts, water demand will already exceed supply by 40% in 2030. That is a dramatic forecast and should wake us up. Of course, climate change is an influencing factor. The increasing water consumption of agriculture in the wake of the growing population presents us with major challenges. In addition, water treatment plays a central role. Some promising investment ideas can be derived from the scarcity problem of the vital resource water.

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: Memiontec Holdings Limited | SGXE56008290 , BAYER AG NA O.N. | DE000BAY0017 , AURUBIS AG | DE0006766504

Table of contents:


    MEMIONTEC HOLDINGS LTD - Business is going well

    Memiontec Holdings is a provider of complete water management solutions in Asia. Recently, the Singapore-based Company reported that it could secure three new orders in Indonesia with a total value of SGD 5.5 million. With these new orders, the current order backlog has grown to approximately SGD 81.6 million. The new orders relate to two wastewater treatment projects and one water treatment project in Indonesia. The need in the island nation is huge; almost every second Indonesian has no access to clean water.

    Memiontec is focusing on the fast-growing cities in China, Indonesia and mainly on the city-state of Singapore. The water and wastewater management specialist serves several demand groups, including municipalities, cities and industrial companies. The Company covers the entire value chain in the water segment with complete solutions for freshwater and wastewater management as well as water treatment solutions.

    With the recently published half-year figures, the Company documents that business is going well. Sales climbed by 86% to SGD 27 million. Profit increased at an enormously disproportionate rate. Profit after tax multiplied from a low base to SGD 0.48 million. Earnings per share increased from SGD 0.01 to SGD 0.22. The Company is currently valued at SGD 54 million.

    BAYER AG - Renewed burdens

    Agriculture accounts for about 70% of the world's freshwater consumption. Water will soon become a decisive bottleneck factor in agriculture in regions with water shortages. In this context, the DAX-listed Company focuses its agrochemicals business on targeted research activities to ensure water-efficient agriculture. Bayer is also developing products and technologies for improved wastewater treatment. In the media, the legacy from the acquisition of US competitor Monsanto is present. Here, several lawsuits are pending against Bayer in the US over a carcinogenic fertilizer. The Group also has a strong pharmaceuticals business.

    The most recently published half-year figures were disappointing. High costs and negative exchange rate effects weighed on results. Due to renewed provisions for possible charges in the US glyphosate litigation, the Group posted a billion-dollar loss in the second quarter. These charges will also lead to a significant drop in profits for the full year, even though Bayer recently raised its sales outlook for 2021. Analysts believe the Group will again post a substantial profit of just under EUR 5 billion in 2022. Thus, the 2022 P/E ratio is a moderate 10.

    AURUBIS AG - Share corrects from all-time high

    Aurubis is one of the world's leading copper recyclers and suppliers of non-ferrous metals. Because of limited resources, the recycling economy is of great importance. Every year, the Hamburg-based company produces more than 1 million tons of marketable copper cathodes with a purity content of 99.99% in its European smelter network. These are then processed into a wide variety of copper or copper alloy intermediates.

    At the end of July, the shares reached a new all-time high of EUR 87. Shortly after that, with the presentation of the nine-month figures, a price correction set in. The good quarterly figures were not good enough. In addition, some market participants had expected an increase in the annual targets.

    Aurubis benefited from high metal prices in the wake of the global economic recovery and rising demand due to the growth in electromobility. The Group collected high refining charges for copper scrap (recycling) and sulfuric acid, which is produced in copper production. Earnings before taxes almost doubled in Q3 to EUR 83 million. After nine months, the Hamburg-based company can look back on a pre-tax profit of EUR 268 million, more than double the figure for the same period last year. Higher energy prices had a negative impact in Q3.


    Resources are finite. We all know that, but we do not act accordingly. An ever-growing world population and increasing demand for resources, coupled with climate change, suggest that the balance will be lost. Water is a key example. With stocks like Bayer and Memiontec, investors can bet on innovative players in the field of "water". Bayer is a global Company with several business units. Memiontec is a more focused way to profit from the investment trend.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Armin Schulz on January 26th, 2022 | 11:17 CET

    Novavax, CoinSmart, Netflix - A buy after significant setbacks?

    • Investments

    The last few weeks have been tough for vaccine makers, cryptocurrencies and tech companies. In the case of vaccine manufacturers, concerns about a possible endemic disease caused by OmiCron was the reason for falling prices. In addition, there were the rumors about Pfizergate. Cryptocurrencies have been consolidating since early November. Allegedly, the US government is planning a crypto law, but contents are not yet known. For tech companies, the FED's expected interest rate hike, likely to be announced on January 26, brings uncertainty and makes investors rethink their investment strategy. Out of tech stocks, into value stocks. We look at one Company from each sector today.

    Read

    Commented by André Will-Laudien on January 20th, 2022 | 12:51 CET

    Alibaba, Hong Lai Huat, Tencent: Now things are really taking off!

    • Investments

    The Asia region remains on the growth path. The economies of China, Singapore, and Indonesia achieved 4.5 to 6.5% growth in 2021. Prosperity is not yet comparable with the West. But the developed zones around the metropolises have already shown high momentum for years. The real estate market, in particular, is booming in China as well as in Hong Kong, Singapore and Japan. It is uncertain how long the low interest rates will continue to support these markets because the Federal Reserve has already announced that it will exit the liquidity bubble. Who can surprise in the current environment?

    Read

    Commented by Mario Hose on January 20th, 2022 | 11:08 CET

    Cardiol, Novavax, Valneva - Why it's worth buying now!

    • Investments

    The trading week is coming to an end and on Thursday the German benchmark index DAX continues to trade below the psychological mark of 16,000 points at a level of 15,785 points and an increase of 0.10%. The rest of today and Friday remain to make a jump. It will probably depend on the guidance from the U.S., but at the hour, U.S. futures are all green. MDAX last traded at 34,135 points (+0.07%), TecDAX at 3,544 points (+0.07%) and SDAX at 15,626 points up 0.33%. Companies from the biotech sector are again in the focus of the investors today.

    Read